Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine.
A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with > or = four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p<0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p<0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.
Hepburn
M J
MJ
Division of Medicine, United States Army Medical Research Institute for Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA. matthew.hepburn@amedd.army.mil
Kortepeter
M G
MG
Pittman
P R
PR
Boudreau
E F
EF
Mangiafico
J A
JA
Buck
P A
PA
Norris
S L
SL
Anderson
E L
EL
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D017056:Medical Laboratory Personnel; D008875:Middle Aged; D008889:Military Personnel; D009500:Neutralization Tests; D012189:Retrospective Studies; D013997:Time Factors; D014481:United States; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D022341:Yellow Fever Vaccine